Physician profile
Jean Hsu
NPI 1831169663
$1,272.81
in general payments reported to CMS, 2019-2025
10 companies · $909 in 2025
The $909 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $55.22 · 2022: $57.08 · 2023: $231 · 2024: $20.43 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $461.40 | 2022-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $364.87 | 2025 | Xdemvy |
| Alcon Vision LLC | $249.14 | 2025 | Tryptyr, Precision7, Precision 1 |
| Glaukos Corporation | $40.55 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Abbvie INC. | $32.45 | 2023 | |
| Bausch & Lomb Americas INC. | $27.09 | 2023 | Infuse |
| Johnson & Johnson Surgical Vision, INC. | $21.66 | 2023 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Amgen INC. | $20.43 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $16.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.